Summary & Overview
HCPCS Q4189: Artacent ac, 1 mg
HCPCS Level II code Q4189 denotes Artacent ac, 1 mg, an injectable pharmaceutical product used in outpatient infusion or clinic settings. Nationally, accurate coding for single-agent injectable products is important for clinical documentation, claims adjudication, and formulary management. Precise identification of the drug and dosage supports appropriate benefit application and utilization tracking.
Key payers commonly involved in coverage and reimbursement for injectable drugs include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and common billing considerations for outpatient administered medications. The publication outlines payer coverage patterns, common modifier usage, and related administrative factors that affect claim processing and payment outcomes.
This analysis provides benchmarks for payer adoption and coding consistency, highlights policy updates that influence injectable drug billing, and situates Q4189 within clinical administration workflows. The content is intended to inform reimbursement analysts, revenue cycle teams, and clinical billing staff about operational implications and documentation needs associated with HCPCS Level II code Q4189.
Billing Code Overview
HCPCS Level II code Q4189 describes Artacent ac, 1 mg, an administered pharmaceutical product. The service type is injectable medication administration, typically provided in outpatient infusion centers, physician offices, or hospital outpatient departments depending on clinical protocols and payer rules.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult with advanced non–small cell lung cancer (NSCLC) harboring a specific molecular alteration for which Artacent ac (an anti-cancer systemic agent supplied as 1 mg units) is indicated as part of targeted systemic therapy. The patient presents to an outpatient oncology infusion center or hospital outpatient infusion suite for intravenous administration. Prior to treatment, the oncology team confirms diagnostic molecular testing results, reviews current laboratory values (CBC, CMP), assesses performance status, documents informed consent, and verifies insurance eligibility. On the day of service, an oncology nurse performs line assessment (peripheral IV or implanted venous access), prepares weight- or body-surface-area–based dosing using the 1 mg unit vial(s), and a pharmacist compounds the dose in an appropriate sterile environment. The infusion is administered with standard premedication and monitoring per the drug label and institutional protocol. Typical documentation includes the drug name and HCPCS code Q4189, total milligrams administered, lot number, NDC, route, infusion start and stop times, infusion site, patient tolerance, and any adverse reactions. Billing may require application of clinically relevant modifiers for unusual circumstances (e.g., increased procedural services, discontinued service, or use of an implanted port), and the encounter is coded with the primary oncologic diagnosis (ICD-10) that justifies systemic therapy.
Coding Specifications
| Modifier | Description |
|---|